Current oncology最新文献_第6页

The Role of Insulin Resistance in Cancer. 胰岛素抵抗在癌症中的作用。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-25 DOI: 10.3390/curroncol32090477

Bal Krishna Subedi, Charishma Bhimineni, Shivani Modi, Atousa Jahanshahi, Katherine Quiza, Daniel Bitetto

引用次数: 0

Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis. 局部前列腺癌的局灶治疗：一个具有成本分析的病例系列。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-23 DOI: 10.3390/curroncol32090476

Maxwell Sandberg, David Thole, Jackson Nowatzke, Gavin Underwood, Emily Ye, Soroush Rais-Bahrami, Ronald Davis, Alejandro Rodriguez

{"title":"Focal Therapy for Localized Prostate Cancer: A Case Series with Cost Analysis.","authors":"Maxwell Sandberg, David Thole, Jackson Nowatzke, Gavin Underwood, Emily Ye, Soroush Rais-Bahrami, Ronald Davis, Alejandro Rodriguez","doi":"10.3390/curroncol32090476","DOIUrl":"10.3390/curroncol32090476","url":null,"abstract":"Focal therapy for prostate cancer (PCa) provides approaches to treat PCa patients in a less invasive manner than traditional whole-gland surgical or radiation modalities. This manuscript provides a case series of high-intensity focused ultrasound (HIFU), cryoablation, and irreversible electroporation (IRE) for PCa at a single institution and cost analysis with a review of the literature. All patients who underwent HIFU, cryoablation, or IRE for localized PCa were retrospectively reviewed, excluding patients who received whole-gland therapy. Functional outcomes were erectile dysfunction and lower urinary tract symptoms. Cost data were collected. A total of 45 patients were included in the study with focal therapy ranging from 2023 to 2025 (4 HIFU, 20 cryoablation, 21 IRE). A total of 30 patients had focally treated lesions, and 15 patients had hemi-gland treatment. The mean preoperative PSA was 7.7 ng/mL. On the paired sample t-test, there was no significant difference between pre-focal and post-focal therapy PSA. Three patients experienced biochemical recurrence requiring prostate biopsy after focal treatment. Mean cost was USD 3804.50 and not significantly different by focal treatment. No metastatic events occurred nor deaths at a median follow-up of 6 months. Patients in this series had largely unaltered functional outcomes. Cost analysis in contemporary publications is lacking. Although follow-up was short, cancer control was adequate.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Associated with Quality of Life (QoL) in Adolescents and Young Adults with Cancer. 青少年和青年癌症患者生活质量（QoL）相关因素。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-22 DOI: 10.3390/curroncol32090475

Reanna George, Geoff Eaton, Pam Crotty, Cheryl Heykoop, Norma D'Agostino, Sapna Oberoi, Joshua A Rash, Sheila N Garland

{"title":"Factors Associated with Quality of Life (QoL) in Adolescents and Young Adults with Cancer.","authors":"Reanna George, Geoff Eaton, Pam Crotty, Cheryl Heykoop, Norma D'Agostino, Sapna Oberoi, Joshua A Rash, Sheila N Garland","doi":"10.3390/curroncol32090475","DOIUrl":"10.3390/curroncol32090475","url":null,"abstract":"Adolescents and young adults (AYAs) diagnosed with cancer between the ages of 15 and 39 years face unique challenges that impact their long-term quality of life (QoL). Physical functioning, relationship status, social support, anxiety, and depression have been associated with QoL in AYAs with cancer. This study explored factors associated with increased QoL in a sample of 392 AYAs with cancer in Canada who participated in the initial Young Adult Cancer Canada RECOVER survey. The EORTC QLQ-C30 was used to measure QoL. Adjusting for relevant demographic, cancer, and clinical variables, the only factors significantly associated with QoL in multivariable analysis were symptoms of depression [Mild (β = -0.420, p < 0.001); Moderate (β = -0.937, p < 0.001); Moderately Severe (β = -1.188, p < 0.001); Severe (β = -2.182, p < 0.001)] and generalized anxiety [Mild (β = -0.244, p = 0.012); Moderate (β = -0.420, p = 0.002); Moderately severe (β = -0.400, p = 0.012); Severe (β = -0.697, p = 0.010)], as well as having completed treatment (β = -0.347, p < 0.001). Age, gender, time since diagnosis, having children, education, income, fear of recurrence, and social support were not significantly associated with QoL. These results support the need for age-appropriate resources to help AYAs manage the long-term psychological impacts of cancer.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 9","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12469053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145148275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Construction and Verification of a Predictive Nomogram for Overall Survival in Patients with Large Retroperitoneal Liposarcoma: A Population-Based Cohort Study. 大型腹膜后脂肪肉瘤患者总生存率预测图的构建和验证：一项基于人群的队列研究。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-21 DOI: 10.3390/curroncol32080473

Huan Deng, Zhenhua Lu, Yajie Wang, Lin Xiao, Yisheng Pan

{"title":"Construction and Verification of a Predictive Nomogram for Overall Survival in Patients with Large Retroperitoneal Liposarcoma: A Population-Based Cohort Study.","authors":"Huan Deng, Zhenhua Lu, Yajie Wang, Lin Xiao, Yisheng Pan","doi":"10.3390/curroncol32080473","DOIUrl":"https://doi.org/10.3390/curroncol32080473","url":null,"abstract":"Objective This study aimed to show the clinicopathological characteristics of large retroperitoneal liposarcoma (RLS) and to develop a customized nomogram model for patients with large RLS. Methods A total of 1735 patients diagnosed with RLS were selected from the public SEER database. Among them, 1113 patients with a maximum tumor diameter greater than 150 mm were included for further analysis. Nomogram models were developed based on Lasso and multivariate Cox regression analyses. A total of 166 patients that presented in the same period at our institution were used for external validations. Results A larger tumor size in RLS was associated with worse survival outcomes. Lasso and Cox regression analyses consistently identified age, TNM stage, occurrence pattern, histology, and surgery as important prognostic factors for OS. The constructed model demonstrated robust predictive performance, with better time-ROC (time-dependent receiver operating characteristic) for 1-year (83.1%), 3-year (83.8%), and 5-year (81.4%) survival in the training cohort. The concordance index (C-index) was approximately 0.80 in both the training and validation cohorts, reflecting excellent discriminatory ability of the model. Survival risk stratification analysis revealed significant differences in survival outcomes of large RLS (HR = 4.12 [3.31-5.12], p < 0.001, in the training cohort). Decision curve analysis (DCA) confirmed that the nomogram provided greater net benefits across a range of threshold probabilities. Conclusion This study identified important prognostic factors for survival in patients with large RLS and developed a reliable nomogram for predicting OS. The model's strong predictive performance supports its use in personalized treatment strategies, improving prognosis assessment and clinical decision making for these patients.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Relation Between Post-Operative Surgical Site Infection and Time to Start Adjuvant Treatment in Ovarian and Uterine Cancers. 卵巢癌和子宫癌术后手术部位感染与开始辅助治疗时间的关系。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-21 DOI: 10.3390/curroncol32080474

Karlijn M C Cornel, Julie My Van Nguyen, Lilian T Gien, Allan Covens, Danielle Vicus

{"title":"The Relation Between Post-Operative Surgical Site Infection and Time to Start Adjuvant Treatment in Ovarian and Uterine Cancers.","authors":"Karlijn M C Cornel, Julie My Van Nguyen, Lilian T Gien, Allan Covens, Danielle Vicus","doi":"10.3390/curroncol32080474","DOIUrl":"https://doi.org/10.3390/curroncol32080474","url":null,"abstract":"Surgical site infections (SSIs) occur in 10-15% of patients and are linked to up to 29% of delays in starting adjuvant treatment. This study assessed the association between SSIs in patients with ovarian and uterine cancer and their impact on time to adjuvant therapy and oncologic outcomes. Patients who underwent surgery from 1 January 2015 to 30 September 2017 were included, using institutional National Surgical Quality Improvement Program (NSQIP) data and chart reviews. Among 371 patients (median follow-up 4.1 years), 243 (65.5%) received adjuvant treatment. The median time to start was 39 days for chemotherapy, 61 days for radiotherapy, and 42 days for combined therapy (p < 0.001). Patients with ovarian cancer began treatment sooner than those with uterine cancer (39 vs. 52 days, p < 0.001), but no significant difference was observed between those with or without SSIs. In 238 patients with uterine cancer, those with SSIs had a twofold higher recurrence risk (HR 1.97, p = 0.022) and over threefold lower overall survival (HR 3.45, p = 0.018). Multivariable analysis showed that surgical route and disease stage were independent predictors; SSI was not an independent factor. No survival difference related to SSIs was found in patients with ovarian cancer. Further research is needed to clarify the impact of SSIs on treatment timing and recurrence.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12385515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Disparities, Heterogeneities, and Barriers to Access for Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A National Survey from Brazil. 激素受体阳性、人表皮生长因子受体2阴性转移性乳腺癌患者的治疗差异、异质性和获得障碍：来自巴西的一项全国调查

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-19 DOI: 10.3390/curroncol32080471

Heloisa Resende, Vinícius de Q Aguiar, Nataline F de A Santos, João Vitor Siqueira Jardim, André Ornelas

{"title":"Treatment Disparities, Heterogeneities, and Barriers to Access for Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A National Survey from Brazil.","authors":"Heloisa Resende, Vinícius de Q Aguiar, Nataline F de A Santos, João Vitor Siqueira Jardim, André Ornelas","doi":"10.3390/curroncol32080471","DOIUrl":"https://doi.org/10.3390/curroncol32080471","url":null,"abstract":"Breast cancer (BC) is the most common malignancy among Brazilian women, with a high percentage of the cases diagnosed at advanced or metastatic stages (mBC). In Brazil, where 75% of the population depends on the resource-limited public health system (SUS), mBC poses significant treatment challenges and disparities. To characterize this scenario, we conducted an online survey assessing treatment strategies available for HER2-negative, hormone receptor (HR)-positive mBC across public and private health systems. The 48-question survey addressed topics such as waiting time (WT) from oncology unit entry to treatment initiation, availability of oncologic medications, and access to palliative and multidisciplinary care teams. Between 2 August 2022 and 30 September 2022, a total of 180 oncologists were invited, and 150 met the inclusion criteria. The median WT for surgery was 60 days in the SUS versus 30 days in the private sector (p < 0.0001), and for chemotherapy, 30 days in the SUS versus 15 days privately (p < 0.0001). Endocrine therapy was the preferred first-line treatment in the SUS (83.3%), while fulvestrant was available to only 48% of respondents. Additionally, specialized palliative care teams were available according to 66% of SUS respondents compared with 82% in the private system (p = 0.001). These findings underscore persistent disparities in mBC treatment, likely driven by limited governmental health investment.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer. 免疫检查点抑制剂联合化疗在台湾广泛期小细胞肺癌患者中的实际有效性和安全性。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-19 DOI: 10.3390/curroncol32080472

Cheng-Yu Chang, Yu-Feng Wei, Shih-Chieh Chang, Chung-Yu Chen

{"title":"Real-World Effectiveness and Safety of Immune Checkpoint Inhibitors Combined with Chemotherapy in Taiwanese Patients with Extensive-Stage Small Cell Lung Cancer.","authors":"Cheng-Yu Chang, Yu-Feng Wei, Shih-Chieh Chang, Chung-Yu Chen","doi":"10.3390/curroncol32080472","DOIUrl":"https://doi.org/10.3390/curroncol32080472","url":null,"abstract":"Purpose: Extensive-stage small cell lung cancer (ES-SCLC) has poor prognosis. While immune checkpoint inhibitors (ICIs) with chemotherapy show survival benefits in trials, real-world data from Asia are scarce. This study evaluates real-world efficacy and safety of chemotherapy with or without ICIs in Taiwanese patients with ES-SCLC and identifies survival predictors.Materials and methods: A retrospective cohort study analyzed 114 patients with ES-SCLC treated between 2017 and 2023 at four Taiwanese medical centers. Patients received first-line chemotherapy alone (n = 68) or with ICIs (atezolizumab, durvalumab, pembrolizumab; n = 46). Primary endpoints were overall survival (OS) and progression-free survival (PFS), assessed via Kaplan-Meier methods and Cox regression.Results: Baseline characteristics were comparable, except poorer ECOG performance (≥2) in the chemotherapy group (27% vs. 9%; p = 0.021). IO-chemotherapy significantly improved OS (16.1 vs. 9.4 months; HR = 0.32, 95% CI: 0.20-0.52; p < 0.001) and PFS (7.8 vs. 5.5 months; HR = 0.40, 95% CI: 0.26-0.63; p < 0.001). Multivariate analysis confirmed IO-chemotherapy as an independent positive predictor (OS adjusted HR = 0.25, 95% CI: 0.14-0.44; PFS adjusted HR = 0.37, 95% CI: 0.22-0.61; both p < 0.001). Skin rash was more common with IO-chemotherapy (24% vs. 3%; p < 0.001). Immune-related adverse events (AEs) correlated with improved survival (median OS: 21.4 months with 1-2 AEs, 16.6 months with 3-4 AEs, 12.5 months without AEs).Conclusion: Immunochemotherapy significantly improves survival in Taiwanese patients with ES-SCLC, with manageable toxicity, supporting ICIs' incorporation into standard treatment.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Quality of Discharge Teaching and Post-Discharge Coping Difficulty in Postoperative Lung Cancer Patients: A Chain Mediation Model. 肺癌术后患者出院教学质量与出院后应对困难的关系：链式中介模型

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-18 DOI: 10.3390/curroncol32080468

Minghui Wang, Hailing Tu, Jingfang Hong

{"title":"Association Between Quality of Discharge Teaching and Post-Discharge Coping Difficulty in Postoperative Lung Cancer Patients: A Chain Mediation Model.","authors":"Minghui Wang, Hailing Tu, Jingfang Hong","doi":"10.3390/curroncol32080468","DOIUrl":"https://doi.org/10.3390/curroncol32080468","url":null,"abstract":"The post-discharge coping difficulties experienced by patients can affect their quality of life and the occurrence of unplanned readmissions. This study aimed to explore the chain mediation effect of self-efficacy and readiness for hospital discharge between quality of discharge teaching and post-discharge coping difficulty among postoperative lung cancer patients. This study employed a cross-sectional design and surveyed 358 postoperative patients with lung cancer. Demographic and Disease-Related Data Questionnaire, Quality of Discharge Teaching Scale, General Self-Efficacy Scale, Readiness for Hospital Discharge Scale, and Post-Discharge Coping Difficulty Scale were used. A structural equation model was utilized to explore the mediation effects of self-efficacy and readiness for hospital discharge. The total score for post-discharge coping difficulty among postoperative lung cancer patients was 34.32 ± 10.00. Quality of discharge teaching not only directly negatively predicted post-discharge coping difficulty (β = -0.154, p < 0.05), but also indirectly affected it through the chain mediation effect of self-efficacy and readiness for hospital discharge (β = -0.040, p = 0.001). Healthcare providers should pay attention to postoperative lung cancer patients' post-discharge coping difficulties and formulate targeted discharge teaching strategies to enhance patients' self-efficacy and readiness for discharge to alleviate their post-discharge coping difficulties.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer. 肿瘤靶向衰老：一种新兴的癌症治疗途径。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-18 DOI: 10.3390/curroncol32080467

Satoru Meguro, Syunta Makabe, Kei Yaginuma, Akifumi Onagi, Ryo Tanji, Kanako Matsuoka, Seiji Hoshi, Tomoyuki Koguchi, Emina Kayama, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura, Yoshiyuki Kojima

{"title":"Targeting Senescence in Oncology: An Emerging Therapeutic Avenue for Cancer.","authors":"Satoru Meguro, Syunta Makabe, Kei Yaginuma, Akifumi Onagi, Ryo Tanji, Kanako Matsuoka, Seiji Hoshi, Tomoyuki Koguchi, Emina Kayama, Junya Hata, Yuichi Sato, Hidenori Akaihata, Masao Kataoka, Soichiro Ogawa, Motohide Uemura, Yoshiyuki Kojima","doi":"10.3390/curroncol32080467","DOIUrl":"https://doi.org/10.3390/curroncol32080467","url":null,"abstract":"Since cancer is often linked to the aging process, the importance of cellular senescence in cancer has come under the spotlight. While senescence in cancer cells can serve as a natural barrier against cancer due to its proliferation arrest, its secretory phenotypes and alterations in the surface proteome can paradoxically promote or suppress tumor progression. Senescent cancer-associated fibroblasts, endothelial cells, and immune cells can also contribute to cancer promotion. During therapeutic interventions for cancer, not only their therapeutic effects, but also therapy-induced senescence may have an impact on cancer outcomes. Senotherapeutics, therapy targeting senescent cells, have been reported as novel cancer therapy in recent studies, and the combination of senescence induction and senotherapeutics has been increasingly recognized. Although some clinical trials of senotherapeutic drugs for cancer with or without senescence-inducible therapy are ongoing, there is as yet no satisfactory clinical application. With further research into targeting senescence in oncology, it is expected that senotherapeutics, particularly in combination with senescence-inducing therapy, will become a novel therapeutic strategy.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extended Survival with Pancreatic Carcinosarcoma: A Case Report and Literature Review. 胰腺癌肉瘤延长生存期1例报告及文献复习。

IF 3.4 4区医学

Current oncology Pub Date : 2025-08-18 DOI: 10.3390/curroncol32080470

Tian Xiao, Claire Browne, Morgan Black, Celia Marginean, Elena Tsvetkova

{"title":"Extended Survival with Pancreatic Carcinosarcoma: A Case Report and Literature Review.","authors":"Tian Xiao, Claire Browne, Morgan Black, Celia Marginean, Elena Tsvetkova","doi":"10.3390/curroncol32080470","DOIUrl":"https://doi.org/10.3390/curroncol32080470","url":null,"abstract":"Pancreatic carcinosarcoma is a rare and aggressive malignancy that can mimic pancreatic adenocarcinomas in presentation but often has different disease biology and different responses to conventional treatment for pancreatic adenocarcinoma. Case reports have documented a 5-year overall survival of approximately 13% only if the disease is caught at an earlier stage and is amenable to multi-modality treatment, including surgery, chemotherapy, and radiation. In the advanced stage, treatments do not often provide benefit, and patients may decline rapidly. There are currently no studies demonstrating survival benefits with chemotherapy in patients with metastatic carcinosarcoma, owing to both the rarity and the often late diagnosis of this aggressive entity. We present a case of a 71-year-old male patient diagnosed with metastatic pancreatic carcinosarcoma who received four lines of palliative-intent treatment: gemcitabine and nab-paclitaxel, modified FOLFIRINOX, GTX, and doxorubicin. With careful selection of chemotherapeutic regimen as well as his ability to tolerate four lines of treatment, this resulted in an unprecedented 26-month survival. We also reviewed the literature on the histopathology, diagnosis, and treatment of this rare entity.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 8","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0